SPRB - Spruce Biosciences Inc Stock Price, Fair Value and News

$0.450.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SPRB RSI Chart

SPRB Valuation

Market Cap

18.6M

Price/Earnings (Trailing)

-0.43

Price/Sales (Trailing)

1.94

Price/Free Cashflow

-0.38

SPRB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SPRB Fundamentals

SPRB Revenue

Revenue (TTM)

9.6M

Rev. Growth (Yr)

-27.27%

Rev. Growth (Qtr)

-20%

SPRB Earnings

Earnings (TTM)

-43.1M

Earnings Growth (Yr)

28.41%

Earnings Growth (Qtr)

21.02%

SPRB Price Action

Last 7 days

-4.3%

Last 30 days

-4.3%

Last 90 days

-15.1%

Trailing 12 Months

-81.5%

SPRB Profitability

Return on Equity

-72.86%

Return on Assets

-57.08%

Free Cashflow Yield

-266.55%

SPRB Financial Health

Current Ratio

5.17

Debt/Equity

0.02

Debt/Cashflow

-53.67

SPRB Investor Care

Shares Dilution (1Y)

1.45%

Diluted EPS (TTM)

-1.02

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	10.2M	9.6M	0	0
2023	3.5M	5.5M	8.4M	10.1M
2022	0	0	821.0K	1.5M
2021	0	0	0	119.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Spruce Biosciences Inc

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

CEO	Dr. Javier Szwarcberg M.D., M.P.H.
WEBSITE	sprucebiosciences.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	32

Spruce Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Spruce Biosciences Inc? What does SPRB stand for in stocks?

SPRB is the stock ticker symbol of Spruce Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Spruce Biosciences Inc (SPRB)?

As of Wed Sep 18 2024, market cap of Spruce Biosciences Inc is 18.59 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SPRB stock?

You can check SPRB's fair value in chart for subscribers.

Is Spruce Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether SPRB is over valued or under valued. Whether Spruce Biosciences Inc is cheap or expensive depends on the assumptions which impact Spruce Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SPRB.

What is Spruce Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Sep 18 2024, SPRB's PE ratio (Price to Earnings) is -0.43 and Price to Sales (PS) ratio is 1.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SPRB PE ratio will change depending on the future growth rate expectations of investors.